BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

NCT07328581 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)
Lupus Nephritis (LN)

Interventions

BIOLOGICAL: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following cyclophosphamide-only lymphodepletion

Sponsor

iCell Gene Therapeutics